Efficacy of On-venous Laser Irradiation of Blood on Diabetes Kidney Disease Patients
Launched by CHINA MEDICAL UNIVERSITY HOSPITAL · Sep 6, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Microalbuminuria is the cardinal symptom of diabetes kidney disease (DKD) and is linked to renal function decline. The cardiovascular risk of patients with DKD is much higher than that of the general population, and cardiovascular diseases is the main cause of death in patients with DKD.
We plan to enroll 72 volunteer patients with microalbuminuria. After 1 week waiting period (as the waiting list group), the patients will be randomized to on-venous laser irradiation of blood and low dose OLIB group. Each group will include 36 patients and given intervention three times a week. The interve...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. HbA1C≥6.5 % and ≤ 9%, ±0.5% under past three months
- • 2. eGFR ≥30ml/min/1.73m2 and protinuria ≥30mg/d under ACEI or ARB treatment
- Exclusion Criteria:
- • 1. allergic to laser beans
- • 2. Immunosuppressive drugs had been used in the past six months
- • 3. urine protein over 3.5 g /day
- • 4. Autosomal dominant polycystic kidney disease
- • 5. Lupus nephritis
- • 6. People with mental illness or other mental disabilities are unable to cooperate with the researcher.
- • 7. Those who used non-steroidal analgesics and steroids in the trial period
- • 8. Pregnant or lactating women
About China Medical University Hospital
China Medical University Hospital is a leading healthcare institution dedicated to advancing medical research and enhancing patient care through innovative clinical trials. Affiliated with China Medical University, the hospital is renowned for its comprehensive approach to medical education and research, fostering collaboration between healthcare professionals and academic experts. With state-of-the-art facilities and a commitment to ethical standards, the hospital conducts rigorous clinical trials aimed at improving treatment outcomes across various medical disciplines, contributing significantly to both local and global healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taichung City, North Dist, Taiwan
Patients applied
Trial Officials
YU-CHEN LEE, Ph.D
Study Director
China Medical University, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported